Abstract
The pharmacokinetics of zidovudine in 10 symptomatic HIV-infected men were assessed after administration of the initial 200 mg oral dose at the start of therapy (day 1) and on one occasion during non steady-state conditions of chronic-dose therapy (200 mg every 4 h while awake on day 21-66; 5 doses per day). The following mean (+/- s.d.) pharmacokinetic parameters were determined on day 1 and during chronic therapy, respectively: Cmax (4.09 +/- 2.54 vs 3.82 +/- 1.03 mumol l-1), oral clearance (40.7 +/- 12.9 vs 41.1 +/- 8.4 ml min-1 kg-1) and terminal half-life (68.4 +/- 29.4 vs 65.1 +/- 13.1 min). Mean pharmacokinetic parameters on day 1 were < 10% different (P > 0.34) from those determined during chronic therapy. Differences in means of 21% for clearance and 36% for Cmax could be detected with a power of 80% at the 5% significance level. Intra-subject coefficients of variation were 17% for clearance and 32% for Cmax, respectively. This study suggests that within a group of patients whose stage of HIV infection and general health are relatively stable, first-dose pharmacokinetic parameters provide a good estimate of multiple-dose pharmacokinetic parameters.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Collins J. M., Unadkat J. D. Clinical pharmacokinetics of zidovudine. An overview of current data. Clin Pharmacokinet. 1989 Jul;17(1):1–9. doi: 10.2165/00003088-198917010-00001. [DOI] [PubMed] [Google Scholar]
- Gitterman S. R., Drusano G. L., Egorin M. J., Standiford H. C. Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group. Clin Pharmacol Ther. 1990 Aug;48(2):161–167. doi: 10.1038/clpt.1990.131. [DOI] [PubMed] [Google Scholar]
- Laskin O. L., de Miranda P., Blum M. R. Azidothymidine steady-state pharmacokinetics in patients with AIDS and AIDS-related complex. J Infect Dis. 1989 Apr;159(4):745–747. doi: 10.1093/infdis/159.4.745. [DOI] [PubMed] [Google Scholar]
- Purves R. D. Optimum numerical integration methods for estimation of area-under-the-curve (AUC) and area-under-the-moment-curve (AUMC). J Pharmacokinet Biopharm. 1992 Jun;20(3):211–226. doi: 10.1007/BF01062525. [DOI] [PubMed] [Google Scholar]
- Sahai J., Gallicano K., Garber G., McGilveray I., Hawley-Foss N., Turgeon N., Cameron D. W. The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. Br J Clin Pharmacol. 1992 Jun;33(6):657–660. doi: 10.1111/j.1365-2125.1992.tb04097.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sahai J., Gallicano K., Garber G., Pakuts A., Hawley-Foss N., Huang L., McGilveray I., Cameron D. W. Evaluation of the in vivo effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 1992 Nov;52(5):464–470. doi: 10.1038/clpt.1992.173. [DOI] [PubMed] [Google Scholar]
- Samuels M. E., Koop C. E., Hartsock P. I. Single-use syringes. N Engl J Med. 1991 Apr 4;324(14):996–997. doi: 10.1056/NEJM199104043241415. [DOI] [PubMed] [Google Scholar]
- Singlas E., Pioger J. C., Taburet A. M., Colaneri S., Fillastre J. P. Comparative pharmacokinetics of zidovudine (AZT) and its metabolite (G.AZT) in healthy subjects and HIV seropositive patients. Eur J Clin Pharmacol. 1989;36(6):639–640. doi: 10.1007/BF00637752. [DOI] [PubMed] [Google Scholar]
- Unadkat J. D., Agosti J. M. Problems in pharmacokinetic investigations in patients with HIV infection. Clin Pharmacokinet. 1990 Sep;19(3):172–176. doi: 10.2165/00003088-199019030-00002. [DOI] [PubMed] [Google Scholar]